Our award-winning, multi-asset class global research team's primary goal is to support you in analyzing the pivotal questions that drive your investment decisions. As a market-leading investment bank research house, we bring you differentiated content on global financial markets and securities with coverage of ~3,800 stocks in over 50 different countries.

  • 720
    Analysts, strategists and economists

UBS internal data

  • 3970
    Company stocks
  • 54
    Markets

Featured topics

Global Investment Returns Yearbook 2026

The latest edition highlights what has driven real asset returns over time and what lessons we can draw to help navigate the future.

Read more
Generative AI Head Side Profile

Generative AI Unlocked

Discover the breadth, depth and originality from our award-winning economists, strategists and analysts.

Read more

Our capabilities

Equities Research

We apply the right research instruments for new evidence, to deliver clear insights. Through industry, data and analytical expertise, this team creates differentiated content and industry-leading investment advice to empower your investment decisions.

Economics & Strategy

UBS Economics draws on the expertise of market strategists and works closely with company and sector analysts to gain a deeper understanding of the workings of the world economy. UBS Global Strategy helps you track down the drivers and connect them to opportunities across asset classes and regions.

UBS Evidence Lab

Providing insight-ready datasets on companies, sectors and themes across more than 55 specialized areas. Our library of assets covers more than 5,000 companies, all sectors and regions, to deliver company-specific insights for ongoing investment debates.

UBS Evidence Lab

UBS HOLT

Empowering you to make informed decisions by providing a clear, objective framework for comparing and valuing companies worldwide. With over 20,000 companies in our database, you gain a unique and consistent approach to portfolio evaluation, using our powerful tools to help streamline the investment process.

UBS HOLT

Quant Answers

A powerful platform which helps you interpret and manage your exposures and risks, allowing you to tap directly into the innovation being developed by the Quant team at UBS. Delivering portfolio risk forecasting, portfolio style and fundamental analysis plus other data and analysis modules.

Quant Answers

Private Company Research

Built to help you navigate disruption from the private sector, we apply a systematic approach to profiling and assess the competitive positioning of private companies.

UBS Analytical Research Community (UBS-ARC)

A proprietary interconnected research network of top executives, industry leaders, subject matter specialists, academics, and analysts who join the community and connect with the UBS Research platform. Informed by these unique perspectives, we provide you with differentiated research events and content.

UBS-ARC

Latest research insights

Market insights and commentary from our global thought leaders

UBS Global Research Pod Hub

UBS Global Research

Tune in to our episodes for insights on the topics that matter from our global economics, strategy and industry thought leaders at UBS

17 Mar 2026

Breaking down quantum computing – Building towards implementation

In part 2 of our series on Quantum Computing, Paul Schneider sits back down with Madeleine Jenkins to look ahead at what could be. They explain why investors have taken such an interest in this topic, and the practical road towards implementation which could potentially reshape technology, markets, and industries alike. *(This information is subject to a disclaimer at the end of this podcast. Please ensure that you listen to the disclaimer and go to www.ubs.com for further information about UBS).

00:00
11:26

10 Mar 2026

Breaking down quantum computing – bit by bit

In part one of this two-part series, Paul Schneider sits down with Madeleine Jenkins, Tech Hardware analyst, to discuss the mechanics of Quantum Computing and how it works. They explore the risks and opportunities, and why it's relatively low costs could mean the start of the next tech revolution. *(This information is subject to a disclaimer at the end of this podcast. Please ensure that you listen to the disclaimer and go to www.ubs.com for further information about UBS).

00:00
12:41

13 Feb 2026

What is driving the comeback story in biopharma?

With drug pricing cuts easing, investor interest is returning, driven by fresh innovation, active M&A, and rotation into a long—undervalued sector.Dimiter Tassev, UBS Healthcare Advisory Sales Specialist, speaks with Michael Yee, Global Head of Biotechnology Research at UBS investment Bank, about the outlook for US biopharma. *(This information is subject to a disclaimer at the end of this podcast. Please ensure that you listen to the disclaimer and go to www.ubs.com for further information about UBS).

00:00
15:11

04 Feb 2026

Food by 2040: The personalised Nutrition Revolution

Charles Eden, European Chemicals Analyst at UBS Investment Bank, joins Paul Schneider, Head of Markets Focus, to unpack the forces transforming the global food system and the shift toward personalised nutrition. (This information is subject to a disclaimer at the end of this podcast. Please ensure that you listen to the disclaimer and go to www.ubs.com for further information about UBS).

00:00
14:12

20 Jan 2026

Analyst Playbook: The evolving role of data and statistics in research

In this episode, Christopher Clarke sits down with Josh Stone, Head of Energy at UBS, to discuss how analysts use data, and how the value of data is changing in 2026 and beyond. *(This information is subject to a disclaimer at the end of this podcast. Please ensure that you listen to the disclaimer and go to www.ubs.com for further information about UBS).

00:00
09:18
spotify-research-pod-hub-qr-code
apple-research-pod-hub-qr-code

Access via UBS Neo

Your access to informed macro and local market insights direct from our economists, analysts and strategists available across regions, companies and asset classes.